Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Genmab A/SNASDAQ: GMAB

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit grows 23.4% year over year

Q2 FY2026 gross profit of $1.07B rose 23.4% year over year. Sequentially, it rose 28.4% from the prior quarter. Over 3 fiscal years it compounded at -38.3% a year.

Context

  • Gross profit amounted to 91.7% of revenue in FY2025, down 3.7 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.07B+28.4% QoQ
Last fiscal yearDec 2025
$3.41B-83.4% YoY
LTMJun 2026
$3.84B— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.4%——
1 year-83.4%——
3-year CAGR-38.3%——
5-year CAGR——
10-year CAGR——

Gross Profit history

Mixed currencies · from the income statement

Latest · FY2025
3.41B USD
Year-over-year change
—

Gross Profit vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Gross profit amounts to 93.0% of revenue for GMAB, versus a peer median of 88.1%.
GMAB Competitors
Gross Profit for GMAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$5.39B USD+26.6%+14.4%92.6%
GMABGenmab A/SLTM Jun 2026$3.84B USD—-38.3%93.0%
EXELExelixis, Inc.LTM Jul 2026$2.35B USD+9.1%+12.9%96.5%
BNTXBioNTech SELTM Jun 2026€1.87B EUR-18.5%-46.9%70.8%
LEGNLegend Biotech CorporationLTM Sep 2026$774.12M USD+40.6%+129.1%57.0%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$201.75M USD+169.7%—53.2%
RCUSArcus Biosciences, Inc.LTM Jun 2026$110M USD-58.0%+28.4%94.0%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$71.82M USD+2.1%-29.1%90.7%
CGENCompugen Ltd.LTM Mar 2026$63.98M USD+230.5%+113.5%88.1%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$150K USD+31.8%——
Peer median (excluding GMAB) —+21.4%+13.6%88.1%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Revenue8.42B14.51B16.47B21.53B3.72B
Cost of Revenue00226M985M309.24M
Gross Profit8.42B14.51B16.25B20.54B3.41B
Gross Margin100.0%100.0%98.6%95.4%91.7%
Research & Development4.18B5.56B7.63B9.75B1.56B
Selling, General & Admin1.28B2.68B3.3B3.79B602.47M
Operating Expenses5.46B8.24B10.93B13.84B2.16B
Depreciation & Amortization248.99M362M293.62M413M71.06M
EBITDA4.18B7.35B6B9.7B1.34B
EBITDA Margin49.7%50.6%36.4%45.0%35.9%
Operating Income2.95B6.27B5.32B6.7B1.25B
Operating Margin35.1%43.2%32.3%31.1%33.6%
Interest Income197M324M939M995M138.11M
Interest Expense13M21M27M120M61.05M
Other Income / Expenses965M678M316M2.46B(46.04M)
Income Before Tax3.92B6.95B5.64B9.16B1.2B
Pre-Tax Margin46.5%47.9%34.2%42.6%32.4%
Income Tax Expense961M1.49B1.29B1.32B241.19M
Net Income2.96B5.45B4.35B7.84B963.76M
Net Margin35.1%37.6%26.4%36.4%25.9%
EPS (Basic)4.528.346.6012.141.55
EPS (Diluted)4.488.266.6012.141.54
Weighted Avg Shares653.96M653.87M659.15M646.33M621.51M
Weighted Avg Shares (Diluted)660.46M660.1M659.15M646.33M626.92M

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.